Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases Jennifer W. Leiding, MD, Lisa.

Slides:

Advertisements

Similar presentations

JAK-STAT Signaling Pathway.

Advertisements

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

Complementary and Alternative Medicine Use among Allergy Practices: Results of a Nationwide Survey of Allergists Michael H. Land, MD, Julie Wang, MD

Advances in Diagnosing Peanut Allergy

Aleena Banerji, MD, Kimberly G. Blumenthal, MD, MSc, Kenneth H

Laurent L'homme, PhD, David Dombrowicz, PhD

The Natural History of Food Allergy

Volume 52, Issue 3, Pages (March 2010)

Allergy to Surgical Implants

Figure 5 Defects in the JAK–STAT signalling pathway

Chronic rhinosinusitis: Potential new use for topical sulfasalazine

Complementary and Alternative Medicine in Allergy-Immunology: More Information is Needed Leonard Bielory, MD The Journal of Allergy and Clinical Immunology:

Fanny Legrand, PhD, PharmD, Amy D. Klion, MD

Dennis K. Ledford, MD, Sally Wenzel, MD

Shyam Joshi, MD, David A. Khan, MD

JAK inhibitors in dermatology: The promise of a new drug class

Therapeutic pipeline for atopic dermatitis: End of the drought?

Biologic Therapy and Novel Molecular Targets of Severe Asthma

Desensitization to Chemotherapeutic Agents

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy

TNF-α–induced protein 3 (A20): The immunological rheostat

Clinical Management of Food Allergy

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Robert G. Hamilton, PhD, John Oppenheimer, MD

JAK3 Specific Kinase Inhibitors: When Specificity Is Not Enough

Malar Rash in a Child with Chronic Granulomatous Disease

Melkersson-Rosenthal Syndrome

Validation of the Pregnancy Asthma Control Test

Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies Jolan E. Walter, MD, PhD, Jocelyn.

Bruton tyrosine kinase inhibition: Clinical relevance beyond B cells

Advances in Diagnosing Peanut Allergy

Erythematous Candidiasis

Nonadherence to Asthma Treatment: Getting Unstuck

Successful treatment of idiopathic angioedema with ecallantide

Practice Notes from the AAAAI

Management of Difficult-to-Treat Atopic Dermatitis

Repeated Episodes of Anaphylaxis with Normal Serum Tryptase but Elevated Levels of Urinary Prostaglandin D2 Phillip Lieberman, MD The Journal of Allergy.

Penicillin Skin Testing Is a Safe and Effective Tool for Evaluating Penicillin Allergy in the Pediatric Population Stephanie J. Fox, MD, Miguel A. Park,

Phillip Lieberman, MD, Michael Tankersley, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

News & Notes Journal of Allergy and Clinical Immunology

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

Molecular mechanisms of IgE regulation

The Management of Eosinophilic Esophagitis

Phillip Lieberman, MD, David Golden, MD

Melkersson-Rosenthal Syndrome

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

Neetu Talreja, MD, Richard F. Lockey, MD

Sinonasal Papillomas and Natural Killer–Cell Deficiency

Sharon Seth, MD, David A. Khan, MD

Weiguo Chen, PhD, Gurjit K. Khurana Hershey, MD, PhD

Cephalosporin Side Chain Cross-reactivity

Evaluation of Allergen Immunotherapy

Granulomatous-lymphocytic Interstitial Lung Disease in a Patient with Common Variable Immunodeficiency Phil Lieberman, MD, John Routes, MD The Journal.

Autophagy: Nobel Prize 2016 and allergy and asthma research

IL-2– and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets Sven Létourneau, DPhil, Carsten Krieg, PhD, Giuseppe Pantaleo,

Administration of Intravenous Immunoglobulin to a Patient with Hypogammaglobulinemia and Anti-IgA Antibodies Phillip Lieberman, MD, Rima Rachid, MD

News & Notes Journal of Allergy and Clinical Immunology

Reply The Journal of Allergy and Clinical Immunology: In Practice

Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments László Maródi, MD, PhD, Jean-Laurent.

Claus Bachert, MD, PhD, Luo Zhang, MD, Phillippe Gevaert, MD

Practice Notes from the AAAI

IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma Michael Kabesch, MD, Michaela Schedel, MSc, David Carr, MSc, Bernd.

TH9 immunodeficiency in patients with hyper-IgE syndrome

Clinical Management of Atopic Dermatitis: Practical Highlights and Updates from the Atopic Dermatitis Practice Parameter 2012 Peter A. Lio, MD, Margaret.

Pedro Giavina-Bianchi, MD, PhD, Shih-Wen Huang, MD

Kinase inhibitors in clinical practice: An expanding world

News & Notes Journal of Allergy and Clinical Immunology

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases Jennifer W. Leiding, MD, Lisa R. Forbes, MD The Journal of Allergy and Clinical Immunology: In Practice Volume 7, Issue 3, Pages 761-773 (March 2019) DOI: 10.1016/j.jaip.2018.12.017 Copyright © 2019 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Figure 1 Jakinib inhibition of JAK-STAT signaling: Cytokines bind their respective receptors and activate janus tyrosine kinase (JAK) proteins, which, in turn, phosphorylate STAT transcription factors to homodimerize or heterodimerize to the nucleus where they direct gene transcription.Shown in this figure are selected cytokines and the corresponding JAK-STAT signal activated. Further shown is where specific JAK inhibitors (Jakinibs) inhibit the activated JAK protein. *IL-2 and IL-15 receptor each have 3 chains. †IL-27 signals through the gp130 receptor chain and can activate STAT1, STAT3 and STAT5. EPO, erythropoietin; JAK, janus kinase. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, 761-773DOI: (10.1016/j.jaip.2018.12.017) Copyright © 2019 American Academy of Allergy, Asthma & Immunology Terms and Conditions